Related Experiment Videos
1 alpha hydroxycholecalciferol and 25 hydroxycholecalciferol in renal bone disease
Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association
|January 1, 1976
Summary
Both 1-alpha-hydroxycholecalciferol (1-alpha-OH D3) and 25-hydroxycholecalciferol (25-OH D3) improved bone mineralization defects in uremic patients. However, neither treatment fully normalized parathyroid hormone levels, warranting further long-term studies.
Area of Science:
- Nephrology
- Endocrinology
- Bone Metabolism
Background:
- Uremic patients often suffer from secondary hyperparathyroidism and impaired bone mineralization.
- Cholecalciferol derivatives are investigated for managing these complications.
Purpose of the Study:
- To evaluate the efficacy of 1-alpha-hydroxycholecalciferol (1-alpha-OH D3) and 25-hydroxycholecalciferol (25-OH D3) in treating renal osteodystrophy.
Main Methods:
- Oral administration of 1-alpha-OH D3 (4 mug) or 25-OH D3 (200 mug) every other day to uremic patients.
- Serial assessment of serum immunoreactive parathyroid hormone (iPTH), calcium, phosphate, and alkaline phosphatase.
- Transilial bone biopsy for histomorphometric analysis before and after treatment.
Main Results:
- Both 1-alpha-OH D3 and 25-OH D3 reduced hyperparathyroidism in two-thirds of patients.
- Consistent improvement in the bone mineralization defect was observed with both treatments.
- Neither treatment normalized iPTH levels or bone histomorphometry.
Conclusions:
- 1-alpha-OH D3 and 25-OH D3 show potential in managing secondary hyperparathyroidism and bone disease in uremia.
- Long-term efficacy and safety require further investigation due to incomplete normalization of parameters.